1 Transcriptomic Gene Network Profiling and Weak Signal Detection for Prediction

of Ovarian Cancer Occurrence, Survival, and Severity by Integrating Bulk and Single-cell RNAseq Data

4

5 Yanming Li^{1,2}, Mihaela Sardiu^{1,2}, Devin C. Koestler^{1,2}, Fengwei Yang¹, Md Tamzid Islam¹,

6 Stephan Komladzei¹, Murshalina Akhter¹

7 1. Department of Biostatistics & Data Science, University of Kansas Medical Center. Kansas City, KS 66160. USA.

8 $\hfill 2.$ The University of Kansas Cancer Center. Kansas City, KS 66160. USA.

9

10 Abstract

11

12 **Background** Ovarian cancer (OC) is a significant gynecological malignancy characterized by its

13 high mortality rate, poor long-term survival rate, and late-stage diagnosis. OC is the 5th leading

14 cause of cancer death among woman and counts 2.1% of all cancer death. OC survival rates

15 are much lower than other cancers that affect woman. Its 5-year survival rate is less than 50%.

16 Only ~17% of OC patients are diagnosed within the early stage. The majority are diagnosed at

17 an advanced stage, making early detection and effective treatment critical challenges. Currently,

18 the identified OC predictive genes are still very sparse, resulting in pool prognostic performance.

19 There exists unmet needs to identify novel prognostic gene biomarkers for OC occurrence,

20 survival, and clinical stages to promote the likelihood of survival and to perform optimal

21 treatments or therapeutic strategies at the earliest stage possible.

22 Methods Previous RNAseq analysis on OC focused on detecting differentially expressed (DE)

23 genes only. Many genes, although having weak marginal differential effects, may still exude

24 strong predictive effects on disease outcomes though regulating other DE genes. In this work,

25 we employed a new machine learning method, netLDA, to detect such predictive coregulating

26 genes with weak marginal DE effects for predicting OC occurrence, 5-year survival, and clinical

27 stage. The netLDA detects predictive gene networks (PGN) containing strong DE genes as hub

28 genes and detects coregulating weak genes within the PGNs. The network structures of the

29 detected PGNs along with the strong and weak genes therein are then used in outcome

30 prediction on test datasets.

31 **Results** We identified different sets of signature genes for OC occurrence, survival, and clinical

32 stage. Previously identified prognostic genes, such as *EPCAM*, *UBE2C*, *CHD1L*, *TP53*1*CD24*,

33 *WFDC2*, and *FANCI*, were confirmed. We also identified novel predictive coregulating weak

34 genes including *GIGYF2*, *GNPAT*, *RAD54L*, and *ELL*. Many of the detected predictive gene

35 networks and coregulating weak genes therein overlapped with OC-related biological pathways

- 36 such as KEGG *tight junction, ribosome*, and *cell cycle* pathways. The detection and
- incorporation of the gene networks and weak genes significantly improved the prediction
- 38 performance. Cellular mapping of selected feature genes using single-cell RNAseq data further
- 39 revealed the heterogeneous expression distributions of the signature genes on different cell
- 40 types.
- 41 **Conclusions** We established a transcriptomic gene network profile for OC prediction. The novel
- 42 genes detected provide new targets for early diagnostics and new drug development for OC.
- 43

44 Introduction

46 incidence rate, poor survival, late-stage diagnosis, and limited treatment options [1,2]. It ranks 47 as one of the most lethal cancers and the 5th leading cause of cancer death among woman [3]. 48 It counts 2.1% of all cancer death. Ovarian cancer survival rates are much lower than other 49 cancers that affect woman. Its 5-year survival rate is less than 50%. Its survivors often face 50 physical and psychological challenges, including long-term side effects of treatment, infertility, 51 and anxiety about cancer recurrence. Women diagnosed before the cancer has spread have a 52 much higher five-year survival rate than those diagnosed at a later stage. However, only $\sim 17\%$ 53 of ovarian cancer patients are diagnosed within the early stage. The majority of OC cases are 54 diagnosed at an advanced stage, making early detection and effective treatment critical 55 challenges [4].

Ovarian cancer (OC) is a significant gynecological malignancy characterized by its high

56

- 57 Advances in transcriptomic and genomic research have provided new insights in the discovery
- 58 of OC oncogenes. Dozens of OC susceptibility genes, such as *BRCA1* [5-8], *BRCA2* [5-7],
- 59 EPCAM [9,10], TP53 66167bfsi CHD1L [13-15], have been identified over the past decades.
- 60 However, the sensitivity and specificity using only these genes in prognostics remain
- 61 suboptimal. Efforts of using machine learning (ML) methods to identify novel gene biomarkers
- 62 for predicting OC occurrence are still ongoing.
- 63
- 64 Compared to cancer occurrence, less research in the literature has been conducted on
- 65 prediction of OC survival [15,16] and clinical stages [17,18]. It is particularly of scientific interest
- 66 to investigate whether it is the same or different sets of genes that contribute to OC
- 67 development and progression (including survival and clinical stages). Identification of novel
- oncogenes for predicting OC patients' survival and clinical stages would be extremely helpful to
- 69 promote the likelihood of survival and optimal treatment or therapeutic strategies at the earliest
- 70 stage as possible, even after the patients being diagnosed of OC.
- 71
- Through a series of work, Li et al. [19-23] have shown that in cancer-genomic studies, some
- 73 genes, even though having weak marginal differential effects (DE), may still exude strong
- 74 prediction effects on disease outcomes though regulating other strong DE genes. These weak
- 75 DE genes (or weak genes), together with their coregulated strong genes and the coregulations
- between them, form predictive gene networks (PDN). Detecting such PDNs and the weak genes
- therein and integrating them into disease outcome prediction could significantly improve the

- 78 prediction accuracy. In this project, we used a novel cancer-genomics analytical tool that we
- 79 recently developed: netLDA network-based linear discriminant analysis
- 80 (https://github.com/lyqglyqg/netLDA) to detect predictive gene networks and strong/weak
- 81 signature genes for predicting OC occurrence, 5-year survival, and clinical stages, using both
- 82 bulk and single-cell RNAseq (scRNAseq) data.
- 83
- 84 By looking at the gene-gene coregulation networks and weak genes, novel signature genes
- 85 were identified, and the outcome prediction accuracy was significantly increased. The results
- 86 helped with a better understanding of the underlining dynamic mechanisms of OC development
- 87 and progression. They may shed light on promotion of precision medicine and new gene
- 88 therapy development.
- 89

90 Materials

- 91 **Data acquisition and processing**. Bulk RNAseq and clinical data of 419 OC patients from The
- 92 Cancer Genome Atlas (TCGA) program and 88 non-disease controls from The Genotype-Tissue
- 93 Expression (GTEx) project were combined and used as the training data for OC occurrence
- 94 prediction. Bulk RNAseq data in GSE18521 for 53 OC tumor samples and 10 normal ovary
- tissue samples from the Gene Expression Omnibus (GEO) database were used as an
- 96 independent test dataset in the case-control study. There were 11,069 mapped genes on both
- 97 training and test datasets.
- 98
- 99 Bulk RNAseg and survival data from GSE26712 for 195 OC patients were downloaded from 100 GEO and used as the training dataset in the survival prediction. The same types of data for 53 101 OC patients were downloaded from GSE18521 and used as a test dataset. There were 12,645 102 common genes mapped on both datasets. The reason for not using TCGA data as the training 103 data is that TCGA subjects cross a wide range of OC stages, which are heavily confounded with 104 the survival. We did not find a GEO dataset that contains both survival and clinical stage 105 outcomes. Therefore, we used two GEO datasets (both of which contained only late-staged OC 106 patients) as the training and test datasets to alleviate the confounding effect from clinical stages. 107 108 Bulk RNAseq and clinical data from 419 TCGA OC patients and from 77 GSE63885 OC patients 109 were used as the training and test data, respectively, in the OC clinical stage prediction. There
- 110 were 17,490 mapped genes on both training and test datasets.
- 111

Single-cell RNAseq data of 22,153 cells and 47,913 transcripts from GSE229343 were used in
 the scRNAseqs data analysis and cellular mapping for the signature genes selected in each
 study.

115

The RNAseq data went through quality control before analysis using R package edgeR [24] or Seurat [25]. For the bulk RNAseq data, genes with counts less than 10 for more than 70% of the samples were removed from analyses. For the scRNAseq data, cells with UMI numbers below 500, gene numbers below 300 or greater than 6,000, or mitochondrial-derived UMI counts of more than 15% were considered low-quality and were removed [103].

121

122 Methods

123 Three studies were conducted for prediction of different OC outcomes: i) occurrence prediction 124 of OC v.s. healthy, ii) 5-year survival prediction of survival longer than 5 years v.s. shorter than 5 125 years, and iii) severity prediction of clinical stage \leq III v.s. V. The following methods were used in 126 each study.

127

128 PGN and network-based weak gene selections. We use the netLDA [20] in both feature 129 selection and outcome prediction. Figure 1 depicts the major steps of netLDA. First, netLDA 130 selects top strong DE gene as hub genes according to their marginal DE effects. Then for each 131 strong DE gene, netLDA selects its coregulated gene network containing its highly correlated 132 genes (having a Pearson correlation coefficient ρ with $|\rho| > 0.8$). Next, netLDA assigns the 133 following predictive score, or network-adjusted DE effect, to each gene in a selected coregulating network, $PS_i = \sum_{j \in C_i} \Omega_i \ (\overline{E}_i^{(1)} - \overline{E}_i^{(2)})$, where *i* and *j* are gene indices, C_i is the set of 134 135 genes connected to gene *i* through a coregulation path, Ω_i is the precision matrix (inverse of 136 the covariance matrix) that characterizes the coregulation information (directions and strengths) between genes in C_i , and $\bar{E}_j^{(1)}$ and $\bar{E}_j^{(2)}$ are the average expression level of gene *j* in outcome 137 138 groups 1 and 2, respectively. The predictive score integrates, for each targeted gene, how many 139 other genes it coregulates, the strengths and directions of those regulations, and expression 140 levels of its coregulated genes, as well as expression levels of the targeted gene itself. The 141 most predictive genes are selected according to the strengths of their predictive scores. 142 Selected predictive genes with small marginal DE effects are weak coregulating genes. For 143 prediction, netLDA uses only the selected predictive genes and the coregulation network 144 structures between them to predict outcomes on the test data. Figure 2 explains the calculation

- 145 of the predictive scores using toy example data. We also developed permutation tests to
- 146 evaluate the significance of selected individual genes and PGNs.
- 147

148 **Prediction performance comparison with competing ML methods**. We compared the

149 prediction performance of netLDA with other commonly used cancer-genomics ML methods

150 including Lasso [26], Ridge [27], ElasticNet [28], XGboost [29], and linear discriminate analysis

151 (LDA) using only the strong genes and ignoring the coregulatory network structures between

152 them. Prediction sensitivities, specificities, and the areas under the receiver operating

153 characteristic curves (ROC) were evaluated to assess the prediction.

154

Kepler-Meijer analysis. Kepler-Meijer (KM) analysis is a commonly used biomarker validation approach in cancer genomics studies. It compares the survival or KM curves between high- and low- expressed groups of a DE gene [30]. Here we generated KM curves according to the longand short-term survival groups predicted by using the selected strong and weak genes, and their PGN structures. We compared the KM curves to the ones generated from only using the top strong genes' expression levels.

161

Gene set enrichment analysis. To validate our identified genes and PGNs from a biological perspective, we conducted gene set enrichment analysis (GSEA) [31], a knowledge-based approach for interpreting transcriptome profiles, using GeneOntology (GO) [32] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [33] pathways. The selected strong/weak genes and PGNs were mapped to the top enriched KEGG pathways to confirm their oncological functionals.

168

169 Cellular mapping for the selected genes. To reveal the cellular expression heterogeneity of
 170 the selected signature genes, we also performed a scRNAseq analysis for cell type profiling and

- 171 cellular mapping of the selected genes.
- 172

173 **Results**

174 **Predictive gene network and network-based gene selections**. Top selected genes in the

175 three studies are listed in **Table 1**. Marginal expression patterns for the selected genes are

176 depicted in **Figure 3**. Top selected PGNs harboring the selected genes were listed in **Table 2**.

177 Topological structures (illustrating the connection topologies) and connection matrices

178 (illustrating the connection strengths) of the PNGs, along with marginal and network-adjusted

179 DE effects of the genes within, were depicted in **Figure 4**. Most of the selected strong genes 180 have both a significant marginal p-value (from marginal tests) and a significant permutation test 181 p-value ($<10^{-4}$, from a network-based test). While majority of the selected weak genes have only 182 a significant permutation test p-value. This demonstrates that integrating of coregulation 183 between genes helps to promote the significance of weak genes in their empirical distributions. 184 For many of the top selected genes, we found literature evidence supporting their associations 185 with OC (last column in **Table 1**). Most of the selected predictive gene networks have significant 186 permutation test p-values (<0.05). Full lists of the selected genes and PGNs are given in the

- 187 Supplemental Materials.
- 188

189 We confirmed strong genes previously reported. *SMPDL3B* (marginal p-value=8.8×10⁻¹⁸²,

190 network-adjusted permutation p-value < 10⁻⁴) and *SLC34A2* (marginal p-value=1.9×10⁻¹⁹⁰,

191 network-adjusted permutation p-value < 10⁻⁴) were confirmed in the OC occurrence study,

192 TRAFD1 (marginal p-value = 0.0013, network-adjusted permutation p-value < 10⁻⁴) and CHD1L

193 (marginal p-value = 0.0021, network-adjusted permutation p-value < 10⁻⁴) were confirmed in the

194 5-year survival study, and FANCI (marginal p-value = 0.0016, network-adjusted permutation p-

195 value < 10⁻⁴) was confirmed in the clinical stage study. Expression of *SMPDL3B* was found

related to specific aptamers for ovarian tumors, such as AptaC2 and AptaC4, through molecular

197 docking [34]. SLC34A2 overexpression was reported related to development and progression of

198 OC, brain cancer, and pancreatic cancer [35]. *TRAFD1* suppression was observed in ovarian,

199 colon, brain, and renal cancers [36]. *CHD1L* overexpression was reported to augment ovarian

200 carcinoma metastasis [15]. *FANCI* has recently been identified as a new ovarian cancer

201 predisposing gene [37,38]. We also discovered some strong genes not been reported before to

be associated with OC. For example, *ILDR1* (marginal p-value = 2.1×10^{-204} , network-adjusted

203 permutation p-value < 10⁻⁴) in OC occurrence study, and *TRAPPC14* (marginal p-value =

 5.6×10^{-4} , network-adjusted permutation p-value = 2×10^{-4}), *RRP1* (marginal p-value = 0.0019,

network-adjusted permutation p-value = 6×10⁻⁴), and *ZSWIM8* (marginal p-value = 0.0045,

206 network-adjusted permutation p-value = 6×10^{-4}) in 5-year survival study.

207

208 We also identified weak genes in regulations with the strong genes, such as *PPP1CA* (marginal

p-value = 3.3×10^{-9} , network-adjusted permutation p-value < 10^{-4}) and *HMGA1* (marginal p-value)

- $210 = 1.0 \times 10^{-57}$, network-adjusted permutation p-value < 10^{-4}) in occurrence study, *RPS8* (marginal
- 211 p-value = 0.044, network-adjusted permutation p-value = 0.016), *RPL28* (marginal p-value =
- 0.36, network-adjusted permutation p-value = 0.024), and *RPL31* (marginal p-value = 0.042,

- network-adjusted permutation p-value = 0.18) in 5-year survival study, and MAPKAPK5 214 (marginal p-value = 0.0017, network-adjusted permutation p-value < 10^{-4}) and BYSL (marginal 215 p-value = 0.042, network-adjusted permutation p-value < 10^{-4}) in the clinical stage study. 216 PPP1CA is a catalytic subunit gene and plays an essential role in the growth of cancer cells 217 [39]. HMGA1 plays a crucial role in the self-renewal and drug resistance of ovarian cancer stem 218 cells [40]. Ribosomal genes, including RPS8, RPL28, and RPL31, have been recently identified 219 as a novel therapeutic target against high-grade OC [41]. Long noncoding RNA MAPKAPK5-220 AS1 promotes cancer cell proliferation by cis-regulating the nearby gene MK5 [42]. BYSL 221 expression was reported to be elevated and promote tumor cell growth [43]. 222 223 Several novel OC-associated weak genes that have not been reported in the literature before
- 224 were identified in our study, such as GIGYF2 (marginal p-value = 0.35, network-adjusted 225 permutation p-value < 10⁻⁴), GNPAT (marginal p-value = 0.21, network-adjusted permutation p-226 value < 10^{-4}) and *RAD54L* (marginal p-value = 0.066, network-adjusted permutation p-value <
- 227 10⁻⁴) in the clinical stage study.
- 228

213

229 **Table 2** lists the top detected PGNs from each of the three studies. Many of these PGNs are 230 overlapping with the top enriched KEGG and/or GO pathways (also see GSEA results). Genes 231 in a KEGG/GO pathway are biologically validated to be related to systematic biology or 232 oncology. Links between genes in a KEGG/GO pathway are lab-confirmed molecular 233 interaction, reaction, and regulations. Overlapping between our selected PGNs and KEGG/GO 234 pathways can serve as biological evidence of our findings. In the OC occurrence study, one of 235 the two netLDA-detected gene networks contains overlapping genes CLDN7 (weak), CLDN4 236 (weak), CLDN3 (strong) that are also in the *tight junction* pathway (enrichment p-value=1.86×10⁻ 237 ³), *leukocyte transendothelial migration* pathway (enrichment p-value=1.76×10⁻³), and cell 238 adhesion molecules cams pathway (enrichment p-value=2.68×10⁻³). Weak genes TJP3 and 239 *CRB3*, in the same network, are also overlapped in the *tight junction* pathway. The other 240 predictive gene network selected in OC occurrence study contains two weak genes PTTG1 and 241 CDC20 that are overlapping with cell cycle pathway (enrichment p-value=1.85×10⁻⁵). In the 242 survival study, one detected predictive gene network is largely overlapped with ribosome 243 pathway (enrichment p-value=1.97×10⁻³⁰). Twenty-eight out of thirty-one genes in the network 244 are in the *ribosome* pathway, which accounts for 31.8% of the 88 leading genes in the ribosome 245 pathway). In the clinical stage study, multiple detected gene networks overlap with KEGG cell 246 cycle pathway (enrichment p-value=4.40×10⁻⁴), KEGG pathways in cancer (enrichment p-

247 value=8.12×10⁻³). GO DNA replication pathway (enrichment p-value=6.91×10⁻⁹). GO DNA 248 recombination pathway (enrichment p-value=2.09×10⁻⁸), and GO chromosome segregation 249 *pathway* (enrichment p-value=1.49×10⁻⁷). Genes overlapping with *KEGG cell cycle* pathway 250 include MCM2 (strong), CREBBP (weak), ABL1 (weak), PLK1 (weak), MCM4 (weak), MCM6 251 (weak), BUB1 (weak), CDC20 (weak), CCNB1 (weak), ORC3 (weak), SMAD2 (weak), GSK3B 252 (weak), and PCNA (weak). Genes overlapping with KEGG pathways in cancer include PTGS2 253 (strong), KRAS (strong), WNT6 (strong), ABL1 (weak), MTOR (weak), SMAD2 (weak), STK4 254 (weak), CREBBP (weak), MSH3 (weak), RXRB (weak), and GSK3B (weak). Genes overlapping 255 with GO DNA replication pathway include PRIM1 (strong), MCM6 (weak), DDX23 (weak), and 256 WDHD1 (weak). Genes overlapping with GO DNA recombination pathway include MCM2 257 (strong), MCM4 (weak), HMCES (weak), and RUVBL1 (weak). Genes overlapping with GO 258 chromosome segregation pathway include BUB1 (weak), PRC1 (weak), KIF2C (weak), CDC20 259 (weak), PLK1 (weak), and RMI2 (weak).

260

261 Prediction performance comparison with competing ML methods. ROC curves in each 262 study are depicted in Figure 5. In the occurrence study, all methods gave almost perfect 263 prediction results – area under the ROC curve (AUC) equaling 1 – as all top genes (strong and 264 weak) have much significant differentiating effects compared to top genes in the survival and 265 clinical stage studies. In the survival study, netLDA gave an AUC = 0.91, much higher than using 266 only the strong genes and Lasso/Ridge/elasticNet (0.85-0.87). XGboosting gave a comparable 267 AUC of 0.90. In the clinical stage study, netLDA also gave the highest AUC = 0.65, XGboosting 268 gave an AUC = 0.61, and Lasso/Ridge/elasticNet and LDA using only the strong genes gave an 269 AUC around 0.5, similar to a random guess.

270

271 KM analysis. Figure 6 shows the Kepler-Meijer curves and log-rank test results in the 5-year 272 survival study. Figure 6 (a) is for the KM curves and log-rank test between the two netLDA 273 predicted groups using both selected strong/weak genes, and PGN structures. Figure 6 (b-d) 274 are KM curves and log-rank tests between high- and low-expression (above and below the 275 median expression value) groups of top three selected strong genes. The two KM curves were 276 more separated, and the log-rank test p-value were more significant between the netLDA 277 predicted groups than those between the expression level groups from a single strong gene, 278 demonstrating the effects of weak genes and PGNs] in improving the classification results. 279

280 **GSEA**. Figure 7 shows KEGG and GO pathway enrichment analysis results. The left panels are 281 examples of the top enriched KEGG pathways for each of the three studies. Tight junction 282 pathway was enriched in the OC occurrence study (enrichment p-value = 1.86×10^{-3}), ribosome 283 pathway was enriched in the 5-year survival study (enrichment p-value = 1.97×10⁻³⁰), cell cycle 284 pathway was enriched in the clinical stage study (enrichment p-value = 4.40×10^{-4}). Many of the 285 weak genes (highlighted in yellow) overlap with these top enriched pathways, confirming that 286 the weak genes play a biological role in the development and progression of OC. A complete list 287 of enriched KEGG pathways is given in the appendix. The right panels in **Figure 7** list the top 288 enriched GO pathways for each study. Top GO pathways enriched in the occurrence study 289 include cell-cell junction organization (enrichment p-value = 4.26×10^{-10}), tight junction assembly 290 pathway (enrichment p-value = 3.55×10^{-9}), and epidermis development pathway (enrichment p-291 value = 7.00×10^{-9}). Top GO pathways enriched in the survival study include SRP-dependent 292 cotranslational protein targeting to membrane (enrichment p-value = 2.54×10^{-55}) and nuclear-293 transcribed mRNA catabolic process (enrichment p-value = 2.16×10^{-53}). Top GO pathways 294 enriched in the clinical stage study include DNA replication (enrichment p-value = 6.91×10^{-9}) 295 and recombinational repair (enrichment p-value = 1.59×10⁻⁷). **Table 3** lists the top enriched 296 KEGG pathways. Lists of top enriched GO pathways are provided in the Supplemental 297 Materials.

298

299 Cellular mapping for the selected genes using scRNAseq data. Figure 8 shows the cellular 300 distribution of the GSE229343 scRNAseq data and the expression maps of the selected feature 301 genes. In Figure 8 (a), Seurat was first used to identify 28 cell subtype clusters using resolution 302 = 0.2. For OC occurrence study, many genes are expressed on epithelial cells (including strong 303 genes: CLDN3, SLC34A2, SMIM22, FOLR1, and weak genes: CLDN7, MAL2, SPRINT1, 304 PRSS8, EHF, ELF3, KRT8, SLPI, KRT18, EPCAM, VAMP8, KRT7, CLDN4, WFDC2, CD24, 305 *MSLN*); on fore/mid/hindgut epithelial cells (including strong genes: *CLDN3*, *SMIM22*, and weak 306 genes: CLDN7, MAL2, SPINT1, PRSS8, ELF3, KRT8, SLPI, KRT18, EPCAM, KRT7, CLDN4); 307 on cycling neural program/mesenchymal stem cells (including weak genes: UBE2C. CDC20. 308 PTTG1, UBE2T); on airway/retinal epi/ciliated cells (including strong genes: CLDN3, SMIM22, 309 FOLR1, and weak genes: ELF3, KRT8, UCP2, SLPI, EPCAM, KRT7, CLDN4, WFDC2, CD24); 310 on myeloid/T cells (including weak genes: UCP2, VAMP8); and on immature neuron cells 311 (including weak gene CD24). For the clinical stage study, many genes are overexpressed on 312 cycling neural program/Mesenchymal stem cells (including weak genes: CDC20, UBE2T. 313 NUSAP1, CCNB1, PLK1, ASPM, PRC1, KIF20A); on immature neuron cells (including strong

gene TUBB2B); and on myeloid cells (including weak gene CD163). For the survival study, as

there were very few genes mapped to the scRNAseq GSE229343 gene set, we did not observe

- a particular cellular express pattern for the selected genes.
- 317

318 Summary and Discussion

319 We confirmed previously identified prognostic genes such as *EPCAM*, *UBE2C*, *CHD1L*, *TP53*1

320 *CD24* [53], *WFDC2* [53], and *FANCI* associated with OC occurrence, survival, or clinical stage.

321 We identified novel susceptibility strong genes including: *ILDR1* in ocurrence study,

322 TRAPPC14, RRP1, and ZSWIM8 in the survival study, as well as novel coregulating weak

323 genes including GIGYF2, GNPAT, RAD54L, and ELL in the clinical stage study. Our identified

324 gene networks overlapped with KEGG tight junction, leukocyte transendothelial migration, and

325 *cell cycle* pathways in the occurrence study; with *ribosome* pathway in the survival study; and

326 with *cell cycle* pathway and *pathways in cancer* in the clinical stage study. We found many

327 identified genes particularly expressed on epithelial cells in the occurrence study and on cycling

328 neural program/Mesenchymal stem cells in the clinical stage study. By incorporating gene

329 network structures and weak genes, netLDA significantly improves the prediction performance

compared to other ML/DL methods such as Lasso, Ridge, elasticNet, XGboost, and LDA with

only strong genes.

332

333 A major contribution of this work is the identification of prognostic oncogenes, especially weak 334 genes in the OC related pathways. The CLDN genes (CLDN7 and CLDN4 detected in the OC 335 occurrence study) in the *tight junction* pathway and *cell adhesion molecules cams* pathway, 336 which functioning as one of the protective barriers in the epithelial and endothelial cells, were 337 also observed to overexpress on fore/mid/hindgut epithelial cells in the single cell analysis. The 338 weak genes detected in the survival study, mainly ribosomal genes, such as RPS8 and RPL28, 339 overlapping with *ribosome* pathway, which was known to promote protein homeostasis in 340 cancers by fine-tuning protein synthesis and preventing toxic protein aggregation [102]. The 341 CCN gene family (CCNB1 detected in the clinical stage study) and CDK genes (CDK2 within the 342 detected network indexed by *PRIM1* in clinical stage study, see **Table 2**, even though it is not in 343 the final selected weak gene set) are coregulating genes in the *cell cycle* pathway. These 344 regulating weak genes were not reported in the literature, as they were difficult to detect by 345 themselves.

347 Although netLDA incorporates gene coregulation network structures into calculating gene 348 differential expressions, it assumes the same network structures (topology, coregulation 349 direction and strength, etc.) between different outcome groups. In real applications, the network 350 structures can be different between groups, in which case a quadratic discriminant analysis 351 might be a better approach. However, accurate and robust inference of different network 352 structures requires large sample sizes per group. Moreover, gene coregulations are usually 353 more stable and robust compared to individual gene expression levels. That is, even individual 354 gene expression levels can vary a lot between different disease groups, cell types, and 355 environments, but the gene-gene coregulation maintains rather stable across the 356 heterogeneous situations. Such robustness in gene networks is critical for assembling a 357 dynamic biology system. Essentially, the network structures inferred by netLDA are the average 358 of different groups when the same network structure assumption is violated. 359

Most of the weak genes selected in the OC occurrence study also have strong marginal DE
 effects. In that sense, they may also be considered as strong genes. The prediction

- 362 performance is dominated by the top strong genes; therefore, the prediction performance 363 (Figure 5) was not much different between netLDA and LDA using only strong genes and other 364 competing methods. The predictive effects of weak genes were manifested in the survival and 365 clinical stage studies, where the marginal DE differential effects of genes are much weaker than 366 that in the occurrence study (Figure 3 and Figure 5). Especially in the clinical stage study, as 367 the strong genes only explained a small portion of the outcome variation on the training data, 368 netLDA dug deeper with more weak genes residing in more predictive networks compared to 369 the occurrence and survival study, in order to accumulate sufficient information to optimize the 370 prediction accuracy on the test data.
- 371

The selected gene sets from the occurrence, survival, and stage studies are non-overlapping. This is mainly because the input gene sets are different for the three studies. Moreover, it also reveals that the OC development and progression may have different underlying molecular mechanisms.

376

Since gene expressions in bulk RNAseq data are averaged expressions over different types of cells, DE effects of some genes might be washed out in the averaging. For example, a gene that is significantly differentially expressed only on a particular cell type but not on other cell types might exhibit only a marginally weak DE effect. A gene differentially expressed on two cell

- 381 types but in different directions will show no marginal DE effect due to signal cancellation. The
- 382 netLDA is a desired method for detecting such genes. It would be an optimal validation
- 383 approach to confirm the DE effects of the selected genes using scRNAseq data from both
- 384 cohorts. Our feature mapping of the selected genes using scRNAseq data helped identify which
- 385 types of cells the genes are particularly expressed on. Investigators are recommended to
- 386 conduct DE analyses using scRNAseq data on the identified cell types to further validate the
- 387 findings.
- 388
- 389

390 Abbreviations

- 391 DE Differentially expressed
- 392 GEO Gene Expression Omnibus
- 393 GO GeneOntology
- 394 GSEA Gene set enrichment analysis
- 395 GTEx The Genotype-Tissue Expression project
- 396 KEGG Kyoto Encyclopedia of Genes and Genomes
- 397 KM Kepler-Meijer
- 398 LDA Linear discriminant analysis
- 399 OC Ovarian cancer
- 400 PGN Predictive gene networks
- 401 RNAseq RNA sequencing
- 402 scRNAseq single cell RNA sequencing
- 403 TCGA The Cancer Genome Atlas











Figure 4, part I. Network topologies of the selected PGNs and strong/weak genes therein. Red nodes represent strong genes and yellow nodes represent weak genes. Node sizes are proportional to their marginal effect sizes. Solid line edges represent positive regulations, dotted line edges represent negative regulations. Strength of connections is represented by the width of the edges. (a-1) Cancer occurrence. (a-2) 5-year survival. (a-3) Clinical stage.









Figure 6. Kepler-Meijer curves and log-rank test results. (a) KM curves and log-rank test between the two netLDA predicted groups: long survival (\geq 5 years) and short survival (\leq 5 years). (b-d) KM curves and log-rank tests between high- and low-expression level (above and below the median expression value) of top selected strong genes. (b) For gene *TRAFD1*. (c) For gene *TTC31*. (d) For gene *CHD1L*.



Figure 7. Gene set enrichment analysis results. Left panels: Example top enriched KEGG pathways and genes therein selected by netLDA. Red: selected as strong genes. Yellow: selected as weak genes. **(a)** Tight Junction pathway (p-value=1.9×10⁻³). **(b)** Ribosome pathway (p-value=2.0×10⁻³⁰). **(c)** Cell Cycle pathway (p-value=4.4×10⁻⁴). Right panels: Top enriched GO pathways. For both left and right panels, **(a)** Cancer occurrence. **(b)** 5-year survival. **(c)** Clinical stage.



Table 1. Top selected genes

Gene name	Gene type	Network-	Permutation p-	Marginal DE	Marginal p-	Literature
		adjusted DE	value for		value+	on selected
			network-			gene
Cancer occurr	ence predictio	n				
BRCA2**	strong		<0.0001*	1 19	<2 2×10 ⁻¹⁶	5-8
BRCA1**	strong		< 0.0001*	1.11	<2.2×10 ⁻¹⁶	5-7
PPP1CA	weak	-0.98	< 0.0001*	2.21	3.3×10 ⁻⁹	39
UBE2C	weak	0.81	< 0.0001*	2.46	3.0×10 ⁻¹³⁴	44-46
SMPDL3B	strong	0.72	< 0.0001*	2.50	8.8×10 ⁻¹⁸²	47
ILDR1	strong	0.71	< 0.0001*	2.50	2.1×10 ⁻²⁰⁴	
SLC34A2	strong	0.61	<0.0001*	2.43	1.4×10 ⁻¹⁹⁰	48
CLDN7	weak	-0.56	<0.0001*	2.45	8.5×10 ⁻⁹⁶	30
EPS8L1	weak	-0.52	<0.0001*	2.35	2.2×10 ⁻⁶⁰	49
HMGA1	weak	0.51	< 0.0001*	2.44	1.0×10 ⁻⁵⁷	50, 51
TMEM238	weak	0.49	< 0.0001*	2.43	1.1×10 ⁻¹¹⁶	52
INAVA	weak	0.46	<0.0001*	1.41	4.2×10 ⁻¹²⁵	53
CDC20	weak	0.43	<0.0001*	-0.44	1.3×10 ⁻¹⁰¹	54
SPINT1	weak	-0.38	<0.0001*	4.43	6.7×10 ⁻⁶⁰	55
SMIM22	strong	0.35	<0.0001*	0.87	1.2×10 ⁻¹⁸⁴	56
5-year surviva	prediction	·	·			
TRAFD1	strong	-0.64	<0.0001*	-0.64	0.0013	57
ADPGK	strong	-0.63	<0.0001*	-0.63	6.4×10 ⁻⁵	58
CHD1L	strong	-0.61	<0.0001*	-0.61	0.0021	59-62
PIAS3	strong	-0.60	<0.0001*	-0.60	0.0018	63
TTC31	strong	-0.63	0.0002*	-0.63	1.8×10 ⁻⁴	64
TRAPPC14	strong	-0.61	0.0002*	-0.61	5.6×10 ⁻⁴	
TRPM4	strong	-0.58	0.0003*	-0.58	0.0014	65
TMEM214	strong	-0.56	0.0004*	-0.56	0.0013	66
IMPDH2	strong	0.56	0.0004*	0.56	0.0043	67
CNOT9	strong	-0.56	0.0005*	-0.56	2.6×10 ⁻⁴	
PLD2	strong	-0.55	0.0005*	-0.55	0.0036	68
CTNNBIP1	strong	-0.56	0.0006*	-0.56	9.5×10 ⁻⁴	69
RRP1	strong	-0.55	0.0006*	-0.55	0.0019	
ZSWIM8	strong	-0.55	0.0006*	-0.55	0.0045	
SRPK2	strong	-0.54	0.0006*	-0.54	0.0018	70
FHOD1	strong	-0.54	0.0007*	-0.54	0.0024	71
RBM7	strong	0.54	0.0007*	0.54	<0.0019	72
RPS8	weak	1.45	0.016*	0.47	0.044	73
RPL28	weak	-1.27	0.024	0.22	0.36	74
RPL31	weak	-1.06	0.042	0.29	0.18	75
Clinical stage	<iv iv="" pred<="" td="" vs.=""><td>liction</td><td></td><td></td><td></td><td>1</td></iv>	liction				1
MAPKAPK5	weak	-1.63	<0.0001*	-0.57	0.0017	76
BYSL	weak	-1.62	<0.0001*	-0.47	0.042	77, 78
GIGYF2	weak	1.16	<0.0001	0.57	0.35	
TGOLN2	weak	-1.10	<0.0001	0.24	0.073	80
TSC2	weak	0.96	<0.0001	0.35	0.22	81
SNX5	weak	0.91	<0.0001	0.14	0.37	82
PIPRA	weak	0.86	<0.0001	-0.50	0.18	83
GNPAI	weak	0.84	<0.0001	0.23	0.21	
RAD54L	weak	-0.81	<0.0001	0.40	0.066	
FANCI	strong	-0.77	<0.0001*	0.35	0.0016	84, 85
MAP3K7	weak	-0.76	<0.0001*	0.24	0.0045	86
	weak	0.69	<0.0001	-0.42	0.47	
HNRNPLL	weak	-0.67	<0.0001	-0.33	0.057	8/
MAP4K3	weak	0.67	<0.0001	0.26	0.50	88
INRC6A	weak	0.67	<0.0001	-0.11	0.32	89,90

DDX23	weak	-0.66	<0.0001*	-0.27	0.027	91
CLASP1	weak	0.65	<0.0001	-0.43	0.42	92
WDHD1	weak	-0.64	<0.0001*	0.22	0.026	93, 94
PCNA	weak	-0.64	<0.0001*	-0.59	0.017	95
LRRC75A	strong	-0.63	<0.0001*	-0.59	0.0016	96
SNRPB	weak	0.62	<0.0001	-0.05	0.13	97
UBN2	weak	0.61	<0.0001	0.80	0.46	98
KIF2C	weak	0.60	<0.0001	-0.14	0.41	99
RAD52	weak	-0.57	< 0.0001*	-0.46	0.026	100, 101

+ Permutation p-value calculated from permutation test of running the netLDA on the selected gene networks 10,000 times.

 Marginal p-value calculated from two-sample t test on each individual gene.
 * Weak gene that has a significant permutation test p-value at level .05 and a significant marginal p-value at level .05.

** BRCA1 and BRCA2 genes were not selected by netLDA as strong genes, as they were both filtered out in the data preprocessing by edgeR due to the facts that 84% of samples have counts <10 for BRCA1 and 93% of samples have counts <10 for BRCA2. By default, edgeR requires a minimum count of 10 for samples. We included them in the table because they were widely reported to be associated with ovarian cancer in the literature. Their marginal p-values were achieved from marginal t-tests.

Network	Network	Strong	Connect genes and selected weak	Permutation
index hub	size	gene(s)	genes within network	network p-
gene		within		value
		network		
Cancer oco	currence pr	ediction	1	1
ILDR1	31	CLDN3, ILDR1,	CLDN4, PRSS8, ELF3, EPCAM, ESRP1, KDF1,	<0.0001
		AP1M2,	C1orf210, GRHL2, KRT8, CLDN7, CRB3, MAL2,	
		OVOL2,	ST14, SPINT1, TJP3, KRT7, GRB7, MARVELD2,	
		SMPDL3B	ESR, COUTTS2, TMPRSSS, PRPS, MSEN, EPS8L1 TMC4	
SLC34A2	29	KLK8, KLK7,	FAM83H, KLK6, EHF, TMEM238, VAMP8,	<0.0001
		SLC34A2,	PPP1CA, UCP2, ZDHHC12, RGS19, BSPRY,	
		SMIM22	SAMD10, HMGA1, TPD52, INAVA, KRT18,	
			CD24 CRABP2 PTTG1 UBE2T CDC20	
5-vear surv	vival predic	tion		
RPS3	31	RPS3	RPS8, RPL31, RPS18, RPS24, RPS23, RPL27A,	<0.0001
			RPS14, RPS29, RPS15A, RPS13, RPL35A,	
			RPS3A, RPL30, RPS15, RPLP1, RPS27, RPL7,	
			RPL70, RPL70, RPL73A, RPS71, RPL20, RPS79, RPL29 FFF1A1 TPT1 RPS4X RPS17 RPL41	
			RPL10	
Clinical sta	age <iv td="" vs.<=""><td>IV prediction</td><td></td><td></td></iv>	IV prediction		
PRIM1	31	PRIM1, SENP1	CDK2, DDX23, RACGAP1, TUBA1B, HNRNPL,	0.024
			WDR76, HAUS2, MCM6, CIDSPL2, NUSAP1, IMNB1 REC5 GATC LING RNE34 ANARCZ	
			<i>PWP1</i> . <i>RMI1</i> . UBQLN1 . C9orf64. ZNF367. NAA35.	
			NCBP1, WDHD1, SOCS4, DLGAP5, EXOC5,	
			POLE2, MAPK1IP1L	
PLEKHM3	31	PLEKHM3	SRCAP, HCFC1, POM121, POM121C, YLPM1,	0.032
			ISP34 PUM2 MED1 CDK12 SYNRG	
			GPATCH8, FBXL20, KANSL1, MGA, TP53 , INO80,	
			VPS39, ZNF106, ZSCAN29, ZBTB40, UBR4,	
	24		SPEN, CLCN6, MTOR, RBM33	0.0004
PDKI	31	PDK1, PPFIA4	WDR75 DCAF17 TIK1 METTI8 CWC22	0.0064
			PRPF40A, SSB, PRKRA, PLEKHA3, UBE2E3,	
			BZW1, OLA1, SUMO1, ATF2, SF3B1, CREB1,	
			NCKAP1, NFE2L2, HNRNPA3, PFKFB4, HK2,	
PNET2	31	DNET2	KDM3A, SLC2A1, OXSR1 SART3 RPAD NAA25 PROMA ATYN2 RTPN11	<0.0001
NNI 12	51		C12orf43. SPPL3. EIF2B1. DENR. VPS33A.	NO.0001
			DIABLO, IFT81, USP30, ZNF84, MAPKAPK5,	
			C12orf76, RSRC2 , SFSWAP , DDX51, RBM19,	
			FBRSL1, SBNO1, PUS1, KDM2B, CAMKK2,	
IOCC	31	IQCC	S100PBP. RBBP4. TXLNA. BSDC1. KPNA6.	0.0020
			ZMYM4, CEP85, EYA3 , PDIK1L, EXOSC10,	0.0020
			HP1BP3, MFN2, ZMYM1, ZMYM6, IPP, PUM1,	
			REV1, GPBP1L1, SNRNP40, ZCCHC17, EIF3I,	
			SRSF4 UBXN11 ZBTB8OS TRNAU1AP	
RPRD1A	31	RPRD1A,	ELP2, ZNF24, SLC39A6, ZNF397, ZSCAN30,	0.0001
		PIK3C3	TRAPPC8, C18orf21, INO80C, RNF138, TPGS2,	
			SINKPUT, IERSIPT, SMAD4, EPG5, SMAD2, DYM, MBD1 7NE396 KIAA1328 TTC30B ESCO1	
			LZTFL1. HDHD2. HNRNPLL. XPO1. MAP4K3	
			ZFR, DHX9, FBX011	
RHOBTB1	31	RHOBTB1	CHSY1, AKAP13, ASB7, MEF2A, ABHD2, TCF12,	<0.0001
			UPY19L1, KBTBD2, HERPUD2, AZI2, MCFD2,	
			JARID2 , TET1, ACVR2B. SALL2. ZNF660.	

Table 2. Top selected predictive gene networks

			FAM117B, ZNF605, ZNF697 , DCHS1, ADAMTS7,			
KRAS	31	KRAS	FAMB1, ITAM2, SLIMATA FGFR10P2, KLHL42, ETNK1, MRPS35, TM7SF3, STK38L, RECQL, GOLT1B, STRAP, WBP11, C12orf4, AEBP2, IPO8, DNM1L, ATF7IP, CCDC91, MATR3, ATF6, C2CD5, CMAS, PLEKHA5, PYROXD1, ATN1, TULP3, RPAP3, SCAF11, ATF1 , ASB8, TWF1 , CCNT1	0.019		
SLC1A4	31	SLC1A4	IMMT, KCMF1, USP39, CIAO1, PTCD3, MRPL35, SMC1A, KDM5C, HUWE1, MED14, DDX3X, POLA1, VCP, UBAP1, UBE2R2, TESK1, DNAJA1, SMU1, ACTR2, RAB1A, PPP3R1, UGP2, RAB10, AFTPH, TEX261, PCBP1, TMEM127, DCTN1, TGOLN2, STAU1	0.0001		
CEP97	31	CEP97	ZBTB11, TBC1D23, PCNP , ZNF143, CGGBP1, ZNF148, SPICE1 , GTF2E1, GSK3B , SLC35A5 , BBX, TFG, SENP7, ZBTB41, NSUN3 , RCOR3, DDX17, WDR11, ARL6 , CPOX, CLDND1, ABHD10 , EFCAB7, LANCL1, CCP110, THUMPD1, KNOP1, COQ7, ERI2, NFATC2IP	0.0028		
ZNF669	31	ZNF669	ZNF670, ZNF124, CNST, DESI2, B3GALNT2, SPRTN, AHCTF1, HNRNPU, ARID4B, HEATR1, WDR26, RAB3GAP2, COG2, GNPAT, TAF5L, IARS2, TSNAX, EXOC8, SH3BP5L, ZNF672, PARP1, ZNF496, PGBD2, TRIM11, RBBP5, KLHL12, CDC73, DSTYK, NUCKS1, RPS6KC1	0.00030		
C20orf96	31	C20orf96	SOX12, ZCCHC3, IDH3B , NRSN2, PSMF1, UBOX5 , PCED1A , RBCK1, CRLS1, MRPS26, ITPA, CDS2, DZANK1, EFHC1, BBS5, TASP1, NEK11, NPHP1 , DHX35, CTNNBL1, DDX27, CDK5RAP1 , SRSF6, UQCC1, BTBD3, RBBP9, GZF1, PBRM1, SPAST, MSL1	0.011		
MYEF2	31	MYEF2	GABPB1, ARPP19, COPS2, DTWD1, USP8, ANP32A, SLTM, SON, RTF1, PRRC2C, DPP8, SP1, TCERG1, RBM27, DDX46, HNRNPH1, PNN, PRPF38B, SRSF10, SRRM1, PNRC2, SFPQ, HNRNPA2B1, HNRNPDL, HNRNPH3, YTHDC1, HNRNPK, FUS, SIRT1, CTCF	0.0025		
DET1	31	DET1	UNC45A, CRTC3, SEMA4B, SNX1, PEX11A, SCAMP2, TTC23, TM2D3, SSRP1, LRRC28, CSNK1G1, ARPIN, MRPL46, MRPS11, SEC11A, WDR61, ZFAND6, HDDC3, SLC24A1, SPG11, PDCD7, HERC1, PIAS1, DIS3L, SCAPER, ARIH1, DENND4A, CLPX, FBX022, MAN2C1	0.017		
Bolded genes are the selected genes (including both strong and weak genes) within the network.						

Table 3. Top enriched KEGG pathways and their overlapping selected get	ne
networks	

Pathway name	Enrichm ent pval	Enrichm ent padj	NES	Path way size	LeadingEdge genes in pathway	Overlapping with selected genes networks
CC						
KEGG_CEL L_CYCLE	2.36×10 ⁻⁵	1.38×10 ⁻³	1.79	112	E2F2/CDKN2A/CDC45/TTK/PKMYT1/C DC20/CCNA1/BUB1B/PTTG1/SFN/BUB 1/CCNB2/ESPL1/CCNE1/CDK1/CDC6/ MAD2L1/CCNB1/PLK1/E2F3/CDKN2B/C CND1/MCM2/E2F1/CCNA2/MCM4/CHE K1	CDC20/PTTG1
KEGG_LEU KOCYTE_T RANSENDO THELIAL_MI GRATION	1.51×10 ⁻³	2.26×10 ⁻²	1.68	83	CLDN6/CLDN3/CLDN9/CLDN16/CLDN4 /CLDN7/CLDN10/MMP9/VAV3/VAV1/CX CR4/THY1/CLDN1/CYBA/ITGAL/CYBB/ OCLN/RAC2/ITGB2	CLDN3/CLDN4/CLDN7
KEGG_TIGH T_JUNCTIO N	1.63×10 ⁻³	2.26×10 ⁻²	1.63	97	CLDN6/CLDN3/CLDN9/CLDN16/TJP3/C RB3/CLDN4/CLDN7/CLDN10/MYH14/P PP2R2B/PARD6B/PRKCQ/CLDN1/PRK CZ/CGN/OCLN	CLDN3/TJP3/CRB3/CLDN 4/CLDN7
KEGG_CEL L_ADHESIO N_MOLECU LES_CAMS	2.04×10 ⁻³	2.38×10 ⁻²	1.64	85	CLDN6/CLDN3/CLDN9/CLDN16/CLDN4 /CLDN7/CLDN10/HLA- DQA2/CDH1/L1CAM/SDC1/ICOSLG/HL A-DQA1/HLA- DQB1/SELPLG/NRCAM/HLA- DR5/HLA-DOA/CLDN1/ICAM3/HLA- DMB/HLA-DRA/ITGAL/CADM3/HLA- DPA1/HLA-DRB1/VCAN/HLA- DMA/OCLN/HLA- DPB1/ITGB2/CDH2/CD4/ITGB8/NECTIN 1/PTPRC/SDC4/CADM1/ICAM1/SDC3	CLDN3/CLDN4/CLDN7
surv						
KEGG_RIBO SOME	1.97E-30	3.29E-28	3.11	81	MRPL13/RSL24D1/RPS25/RPL36AL/RP L10A/RPS3/RPL30/RPS8/RPS12/RPS2 6/RPL15/RPS23/RPL35A/RPL18A/RPS5 /RPL8/RPS15/RPS20/RPL18/RPL36/RP L9/RPL11/FAU/RPS27/RPS15A/RPL10/ RPS19/RPS13/RPL27/RPL35/RPL5/RPL 23/RPS27A/RPL7/RPS29/RPL35/RPL5/RPL 23/RPS27A/RPL32/RPL28/RPLP2/RPL14/ RPLP1/RPSA/RPL24/RPLP0/RPS6/RPL 3/RPL27A/RPL31/RPS18/RPS16/RPS11 /RPL19/RPL13/RPL13A/RPS17/RPS10/ RPL7A/RPL23A/RPL29/RPS2/RPL41/R PL4/RPL22/RPL38/UBA52/RPS7/RPL12	RPS3 /RPL30/RPS8/RPS2 3/RPL35A/RPS15/RPL18/ RPS27/RPS15A/RPL10/R PS19/RPS13/RPS3A/RPS 4X/RPS24/RPS29/RPL7/R PL28/RPLP1/RPLP0/RPL2 7A/RPL31/RPS18/RPS11/ RPL13A/RPS17/RPL29/R PL41
Stage	0.00044	0.0070	4 75	110	TOFR0/00ND0/0000/0007/F0F1/000	
L_CYCLE	0.00044	0.0072	-1.75	110	45/MCM2/CDC25A/ORC3/RBL1/TTK/E2 F3/E2F5/CCNE1/MCM3/SMAD4/BUB1B/ SMAD2/E2F2/PKMYT1/CCNA2/MAD2L1 /CREBBP/WE1/ESPL1/PCNA/CDK2/S KP2/CCNB2/PLK1/CHEK1/CDC25B/CH EK2/ANAPC7/STAG1/CDKN1C/CCNB1/ CDKN1B/ATM/ORC6/RBL2/CDK1	CDR2/AINAPC/ CCNB2/CCNB1/CDK1 SMAD4/SMAD2 TTK MCM2/MCM3 ORC3 E2F1/RBL1/CCNA2/PLK1 CDC6/BUB1B/PCNA CREBBP
KEGG_BAS AL_CELL_C ARCINOMA	0.0016	0.022	-1.87	35	WNT6/FZD5/GLI2/FZD10/GLI3/WNT10A /FZD2/LEF1/WNT2B/STK36	STK36 WNT6
KEGG_PAT HWAYS_IN_ CANCER	0.0081213 85	0.075	-1.43	237	WNT6/LAMA1/MMP9/CXCL8/TGFB2/FZ D5/GLI2/ARNT2/FZD10/GLI3/BCL2/KRA S/WNT10A/LAMC3/LAMB3/MECOM/E2 F1/FZD2/LEF1/CSF3R/WNT2B/E2F3/CC NE1/IGF1R/STK36/SMAD4/PLCG1/FGF R1/SMAD2/LAMB1/E2F2/PIAS2/CREBB	STK36 CDK2 PLCG1 WNT6 SMAD4/SMAD2 LAMB1 KRAS

					P/CBLB/PDGFB/VHL/CDK2/SKP2/MAP K8/MLH1	E2F1 MAPK8 CREBBP
KEGG_HED GEHOG_SI GNALING_P ATHWAY	0.0145528 4	0.11	-1.68	31	WNT6/LRP2/ZIC2/GLI2/GLI3/WNT10A/ WNT2B/STK36	STK36 WNT6
KEGG_MEL ANOGENES IS	0.021	0.16	-1.48	63	WNT6/FZD5/FZD10/KRAS/WNT10A/PL CB4/ADCY5/GNAO1/FZD2/LEF1/WNT2 B/ADCY7/PLCB1/CREBBP/CREB1/CRE B3L4/ADCY6	WNT6 CREB1 KRAS CREBBP
KEGG_MIS MATCH_RE PAIR	0.062	0.36	-1.51	21	EX01/RFC4/RFC5/RFC3/PCNA/MLH1/P OLD3/MSH2/LIG1/RFC1/RPA1/MSH3/M SH6	RFC5 MSH3 MSH2/MSH6 EXO1/ PCNA
KEGG_GLY COSYLPHO SPHATIDYLI NOSITOL_G PI_ANCHOR _BIOSYNTH ESIS	0.064	0.36	-1.51	19	PIGF/PIGG/PIGN/PIGQ/PIGB/PIGU/PIG O/PGAP1/PIGM/PIGT/PIGX/PIGP/PIGV	PIGN
KEGG_DNA _REPLICATI ON	0.060	0.36	-1.47	33	DNA2/MCM2/RFC4/RFC5/PRIM2/MCM3 /RFC3/PCNA/POLE/POLD3/LIG1/RFC1/ RPA1/POLA1/FEN1	RFC5 POLE FEN1 MCM2 /MCM3 POLA1 PCNA
KEGG_ECM _RECEPTO R_INTERAC TION	0.072	0.38	-1.37	59	COL2A1/LAMA1/SV2A/LAMC3/LAMB3/I TGA7/HMMR/LAMB1/SDC1/THBS4	LAMB1 COL2A1

419 420	Referen	nce
421 422 423	1.	Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61. PMID: 27558151; PMCID: PMC7290868
424 425 426	2.	Stewart C, Ralyea C, Lockwood S. Ovarian Cancer: An Integrated Review. Semin Oncol Nurs. 2019 Apr;35(2):151-156. doi: 10.1016/j.soncn.2019.02.001. Epub 2019 Mar 11. PMID: 30867104.
427 428 429 430	3.	Alexandrova E, Pecoraro G, Sellitto A, Melone V, Ferravante C, Rocco T, Guacci A, Giurato G, Nassa G, Rizzo F, Weisz A, Tarallo R. An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer. Cancers (Basel). 2020 Jun 4;12(6):1470. doi: 10.3390/cancers12061470. PMID: 32512900: PMCID: PMC7352306
431 432	4.	National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
433 434 435	5.	Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [updated 2023 Sep 21]. In: Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University
436 437 438 439	6.	of Washington, Seattle; 1993–2023. PMID: 20301425. Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A. The BRCA Gene in Epithelial Ovarian Cancer. Cancers (Basel). 2022 Feb 27;14(5):1235. doi: 10.3390/cancers14051235. PMID: 35267543; PMCID: PMC8909050.
440 441	7.	Casaubon JT, Kashyap S, Regan JP. BRCA1 and BRCA2 Mutations. 2023 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29262038.
442 443	8.	Takaoka M, Miki Y. BRCA1 gene: function and deficiency. Int J Clin Oncol. 2018 Feb;23(1):36- 44. doi: 10.1007/s10147-017-1182-2. Epub 2017 Sep 7. PMID: 28884397.
444 445 446	9.	Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O, Katabuchi H. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget. 2017 Jul 4;8(27):44312-44325.
447 448 449 450 451	10.	doi: 10.18632/oncotarget.17871. PMID: 28574829; PMCID: PMC5546482. Nunna S, Reinhardt R, Ragozin S, Jeltsch A. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS One. 2014 Jan 29;9(1):e87703. doi: 10.1371/journal.pone.0087703. PMID: 24489952; PMCID: PMC3006225
452 453 454	11.	Zhang Y, Cao L, Nguyen D, Lu H. TP53 mutations in epithelial ovarian cancer. Transl Cancer Res. 2016 Dec;5(6):650-663. doi: 10.21037/tcr.2016.08.40. PMID: 30613473; PMCID: PMC6320227.
455 456 457	12.	Silwal-Pandit L, Langerød A, Børresen-Dale AL. TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harb Perspect Med. 2017 Jan 3;7(1):a026252. doi: 10.1101/cshperspect.a026252. PMID: 27815305; PMCID: PMC5204332.
458 459 460 461	13.	He WP, Guo YY, Yang GP, Lai HL, Sun TT, Zhang ZW, Ouyang LL, Zheng Y, Tian LM, Li XH, You ZS, Xie D, Yang GF. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2. Int J Med Sci. 2020 Aug 29;17(15):2387-2395. doi: 10.7150/ijms.48615. PMID: 32922205: PMCID: PMC7484650
462 463 464 465	14.	Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, Jafri I, Park MN, Alsharif G, Fayad E, Mohamed G, Osman R, Kim B, Zaki MSA. A pan-cancer analysis reveals CHD1L as a prognostic and immunological biomarker in several human cancers. Front Mol Biosci. 2023 Mar 23;10:1017148. doi: 10.3389/fmolb.2023.1017148. PMID: 37033447; PMCID:
466 467 468	15.	PMC10076660. He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D, Yang GF. CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for

469 patients survival. BMC Cancer. 2012 Sep 29;12:437. doi: 10.1186/1471-2407-12-437. PMID: 470 23020525; PMCID: PMC3551745. 471 16. Pawar A, Chowdhury OR, Chauhan R, Talole S, Bhattacharjee A. Identification of key gene 472 signatures for the overall survival of ovarian cancer. J Ovarian Res. 2022 Jan 20;15(1):12. doi: 473 10.1186/s13048-022-00942-0. PMID: 35057823; PMCID: PMC8780391. 474 17. Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, 475 Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung 476 SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J; AOCS Group; Fereday S, 477 Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, 478 Macintyre G, Silva De Silva D, Ramón Y Cajal T, García-Donas J, Hernando Polo S, Rodriguez 479 GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, 480 Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, 481 Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj 482 A. Karpinskyi C. Widschwendter M. Singh N. Kennedy CJ. Sharma R. Harnett PR. Gao B. 483 Johnatty SE, Saver R, Boros J, Winham SJ, Keenev GL, Kaufmann SH, Larson MC, Luk H, 484 Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, 485 Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, 486 Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, 487 Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, 488 Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, García MJ, 489 Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny 490 GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic 491 gene expression signature for high-grade serous ovarian cancer. Ann Oncol. 2020 492 Sep;31(9):1240-1250. doi: 10.1016/j.annonc.2020.05.019. Epub 2020 May 28. PMID: 32473302; 493 PMCID: PMC7484370. 494 18. Marchini S, Mariani P, Chiorino G, Marrazzo E, Bonomi R, Fruscio R, Clivio L, Garbi A, Torri V, 495 Cinquini M, Dell'Anna T, Apolone G, Broggini M, D'Incalci M. Analysis of gene expression in 496 early-stage ovarian cancer. Clin Cancer Res. 2008 Dec 1;14(23):7850-60. doi: 10.1158/1078-497 0432.CCR-08-0523. PMID: 19047114. 498 19. Li Y, Hong HG, Ahmed SE, Li Y. Weak signals in high-dimension regression: detection, 499 estimation and prediction. Appl Stoch Models Bus Ind. 2019;35(2):283-98. Epub 2019/11/02. doi: 500 10.1002/asmb.2340. PubMed PMID: 31666801; PubMed Central PMCID: PMCPMC6821396. 501 20. Li Y, Hong HG, Li Y. Multiclass linear discriminant analysis with ultrahigh-dimensional features. 502 Biometrics. 2019;75(4):1086-97. Epub 2019/04/23. doi: 10.1111/biom.13065. PubMed PMID: 503 31009070; PubMed Central PMCID: PMCPMC6810714. 504 21. Li Y. (2020). A Local-Network Guided Linear Discriminant Analysis for Classifying Lung Cancer 505 Subtypes using Individual Genome-Wide Methylation Profiles. In: Arai, K., Bhatia, R., Kapoor, 506 S. (eds) Proceedings of the Future Technologies Conference (FTC) 2019. FTC 2019. Advances in 507 Intelligent Systems and Computing, vol 1069. Springer, Cham. https://doi.org/10.1007/978-3-508 030-32520-6 50. 509 22. Li Y, Kang J, Wu C, et al. A machine-learning approach for detection of local brain networks and 510 marginally weak signals identifies novel AD/MCI differentiating connectomic neuroimaging 511 biomarkers. BioRXiv. doi: https://doi.org/10.1101/2021.07.29.454368. 512 23. Zhou X, Zhang J, Ding Y, Huang H, Li Y, Chen W. Predicting late-stage age-related macular 513 degeneration by integrating marginally weak SNPs in GWA studies. Front Genet. 514 2023;14:1075824. Epub 2023/04/18. doi: 10.3389/fgene.2023.1075824. PubMed PMID: 515 37065470; PubMed Central PMCID: PMCPMC10101437. 516 24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 517 expression analysis of digital gene expression data. Bioinformatics. 2010 Jan 1;26(1):139-40. doi: 518 10.1093/bioinformatics/btp616. Epub 2009 Nov 11. PMID: 19910308; PMCID: PMC2796818.

519 25. Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015 May;33(5):495-502. doi: 10.1038/nbt.3192. Epub 2015
521 Apr 13. PMID: 25867923; PMCID: PMC4430369.
522 26. Tibshirani R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistica

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

- 522 26. Tibshirani R. Regression Shrinkage and Selection via the Lasso. Journal of the Royal Statistical
 523 Society: Series B (Methodological). 1996; 58, 267-288. http://www.jstor.org/stable/2346178.
 524 https://doi.org/10.1111/j.2517-6161.1996.tb02080.x.
 525 27. Hilt DE, Seegrist, DW. Ridge, a computer program for calculating ridge regression estimates.
 - 27. Hilt DE, Seegrist, DW. Ridge, a computer program for calculating ridge regression estimates. 1977; doi:10.5962/bhl.title.68934.
 - Zou H, Hastie T. Regularization and Variable Selection via the Elastic Net. Journal of the Royal Statistical Society, Series B. 2005; 67 (2): 301–320. CiteSeerX 10.1.1.124.4696. doi:10.1111/j.1467-9868.2005.00503.x. S2CID 122419596.
 - Chen TQ, Guestrin C. XGBoost: A Scalable Tree Boosting System. In Krishnapuram B, Shah M, Smola AJ, Aggarwal CC, Shen D, Rastogi R (eds.). Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, CA, USA, 2016 August 13-17, 2016. ACM. pp. 785–794. arXiv:1603.02754. doi:10.1145/2939672.2939785. ISBN 9781450342322. S2CID 4650265.
 - Liu GM, Zeng HD, Zhang CY, Xu JW. Identification of a six-gene signature predicting overall survival for hepatocellular carcinoma. Cancer Cell Int. 2019 May 21;19:138. doi: 10.1186/s12935-019-0858-2. PMID: 31139015; PMCID: PMC6528264.
 - 31. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. doi: 10.1073/pnas.0506580102. Epub 2005 Sep 30. PMID: 16199517; PMCID: PMC1239896.
 - 32. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, Sethuraman A, Theesfeld CL, Botstein D, Dolinski K, Feierbach B, Berardini T, Mundodi S, Rhee SY, Apweiler R, Barrell D, Camon E, Dimmer E, Lee V, Chisholm R, Gaudet P, Kibbe W, Kishore R, Schwarz EM, Sternberg P, Gwinn M, Hannick L, Wortman J, Berriman M, Wood V, de la Cruz N, Tonellato P, Jaiswal P, Seigfried T, White R; Gene Ontology Consortium. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2004 Jan 1;32(Database issue):D258-61. doi: 10.1093/nar/gkh036. PMID: 14681407; PMCID: PMC308770.
 - 33. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000 Jan 1;28(1):27-30. doi: 10.1093/nar/28.1.27. PMID: 10592173; PMCID: PMC102409.
 - 34. Abreu RDS, Antunes D, Moreira ADS, Passetti F, Mendonça JB, de Araújo NS, Sassaro TF, Alberto AVP, Carrossini N, Fernandes PV, Costa MA, Guimarães ACR, Degrave WMS, Waghabi MC. Next Generation of Ovarian Cancer Detection Using Aptamers. Int J Mol Sci. 2023 Mar 28;24(7):6315. doi: 10.3390/ijms24076315. PMID: 37047289; PMCID: PMC10094455.
 - 35. Vlasenkova R, Nurgalieva A, Akberova N, Bogdanov M, Kiyamova R. Characterization of SLC34A2 as a Potential Prognostic Marker of Oncological Diseases. Biomolecules. 2021 Dec 14;11(12):1878. doi: 10.3390/biom11121878. PMID: 34944522; PMCID: PMC8699446.
- 36. Sehovic E, Hadrovic A, Dogan S. Detection and analysis of stable and flexible genes towards a genome signature framework in cancer. Bioinformation. 2019 Nov 10;15(10):772-779. doi: 10.6026/97320630015772. PMID: 31831960; PMCID: PMC6900328.
- 565 37. Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings
 566 E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson
 567 AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Molecular
 568 Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. Genes

569		(Basel). 2023 Jan 20;14(2):277. doi: 10.3390/genes14020277. PMID: 36833203; PMCID:
570	20	PMC9956348.
5/1	38.	Fierheller CI, Guitton-Sert L, Alenezi WM, Revil I, Oros KK, Gao Y, Bedard K, Arcand SL,
572		Serruya C, Behl S, Meunier L, Fleury H, Fewings E, Subramanian DN, Nadaf J, Bruce JP, Bell R,
573		Provencher D, Foulkes WD, El Haffat Z, Mes-Masson AM, Majewski J, Pugh TJ, Tischkowitz
574		M, James PA, Campbell IG, Greenwood CMT, Ragoussis J, Masson JY, Tonin PN. A functionally
575		impaired missense variant identified in French Canadian families implicates FANCI as a
576		candidate ovarian cancer-predisposing gene. Genome Med. 2021 Dec 3;13(1):186. doi:
577		10.1186/s13073-021-00998-5. PMID: 34861889; PMCID: PMC8642877.
578	39.	Takakura S, Kohno T, Manda R, Okamoto A, Tanaka T, Yokota J. Genetic alterations and
579		expression of the protein phosphatase 1 genes in human cancers. Int J Oncol. 2001
580		Apr;18(4):817-24. doi: 10.3892/ijo.18.4.817. PMID: 11251179.
581	40.	Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang
582		K, Lee SC, Kim JH. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian
583		cancer stem cells. Exp Mol Med. 2016 Aug 26;48(8):e255. doi: 10.1038/emm.2016.73. PMID:
584		27561949; PMCID: PMC5007643.
585	41.	Yan S, Frank D, Son J, Hannan KM, Hannan RD, Chan KT, Pearson RB, Sanij E. The Potential
586		of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. Int J Mol Sci. 2017 Jan
587		20;18(1):210. doi: 10.3390/ijms18010210. PMID: 28117679; PMCID: PMC5297839.
588	42.	Yang T, Chen WC, Shi PC, Liu MR, Jiang T, Song H, Wang JQ, Fan RZ, Pei DS, Song J. Long
589		noncoding RNA MAPKAPK5-AS1 promotes colorectal cancer progression by cis-regulating the
590		nearby gene MK5 and acting as a let-7f-1-3p sponge. J Exp Clin Cancer Res. 2020 Jul
591		20;39(1):139. doi: 10.1186/s13046-020-01633-8. Erratum in: J Exp Clin Cancer Res. 2022 Dec
592		13;41(1):341. PMID: 32690100; PMCID: PMC7370515.
593	43.	Gao S, Sha Z, Zhou J, Wu Y, Song Y, Li C, Liu X, Zhang T, Yu R. BYSL contributes to tumor
594		growth by cooperating with the mTORC2 complex in gliomas. Cancer Biol Med. 2021 Feb
595		15;18(1):88-104. doi: 10.20892/j.issn.2095-3941.2020.0096. PMID: 33628587; PMCID:
596		PMC7877178.
597	44.	Li J, Zhi X, Shen X, Chen C, Yuan L, Dong X, Zhu C, Yao L, Chen M. Depletion of UBE2C
598		reduces ovarian cancer malignancy and reverses cisplatin resistance via downregulating CDK1.
599		Biochem Biophys Res Commun. 2020 Mar 5;523(2):434-440. doi: 10.1016/j.bbrc.2019.12.058.
600		Epub 2019 Dec 23. PMID: 318/5843.
601	45.	Martínez-Canales S, López de Rodas M, Nuncia-Cantarero M, Páez R, Amir E, Győrffy B,
602		Pandiella A, Galan-Moya EM, Ocana A. Functional transcriptomic annotation and protein-protein
603		interaction analysis identify EZH2 and UBE2C as key upregulated proteins in ovarian cancer.
604		Cancer Med. 2018 May; 7(5):1896-1907. doi: 10.1002/cam4.1406. Epub 2018 Mar 25. PMID:
605	10	29575713; PMCID: PMC5943485.
606	46.	Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in
607		the progression of thyroid carcinoma. Cell Death Discov. 2022 Mar 24;8(1):130. doi:
608	47	10.1038/s41420-022-00935-4. PMID: 35332135; PMCID: PMC8948250.
609	4/.	Abreu RDS, Antunes D, Moreira ADS, Passetti F, Mendonça JB, de Araujo NS, Sassaro IF,
010		Alberto AVP, Carrossini N, Fernandes PV, Costa MA, Guimaraes ACR, Degrave WMS, wagnabi
011		MC. Next Generation of Ovarian Cancer Detection Using Aptamers. Int J Mol Sci. 2023 Mar
612 (12	40	28;24(7):6315. doi: 10.3390/ijms24076315. PMID: 37047289; PMCID: PMC10094455.
013	48.	viasenkova K, Nurganeva A, Akberova N, Bogdanov M, Kiyamova K. Characterization of
014 615		SLU34A2 as a Polential Prognostic Marker of Uncological Diseases. Biomolecules. 2021 Dec
01J 616	10	14,11(12):10/0. doi: 10.5590/010m111210/0. PMID: 54944522; PMCID: PMIC8099446.
010 617	49.	wang 1, Zhang L, Luo A, et al. EPS6L1 promotes migration and metastasis of ovarian cancer by
618		acuvating Kaci/iviArK Signaling patiway via upregulating TIAIvi2. Authorea. December 10, 2022 DOI: 10.22541/au 167120661.17708120/x1
010		2022. DOI. 10.22341/au.10/120001.1//90120/01.

- 50. Kim DK, Seo EJ, Choi EJ, Lee SI, Kwon YW, Jang IH, Kim SC, Kim KH, Suh DS, Seong-Jang K, Lee SC, Kim JH. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells. Exp Mol Med. 2016 Aug 26;48(8):e255. doi: 10.1038/emm.2016.73. PMID: 27561949; PMCID: PMC5007643.
- 51. Masciullo V, Baldassarre G, Pentimalli F, Berlingieri MT, Boccia A, Chiappetta G, Palazzo J,
 Manfioletti G, Giancotti V, Viglietto G, Scambia G, Fusco A. HMGA1 protein over-expression is
 a frequent feature of epithelial ovarian carcinomas. Carcinogenesis. 2003 Jul;24(7):1191-8. doi:
 10.1093/carcin/bgg075. Epub 2003 May 9. PMID: 12807722.
- 52. Ye C, Ren S, Sadula A, Guo X, Yuan M, Meng M, Li G, Zhang X, Yuan C. The expression
 characteristics of transmembrane protein genes in pancreatic ductal adenocarcinoma through
 comprehensive analysis of bulk and single-cell RNA sequence. Front Oncol. 2023 May
 17;13:1047377. doi: 10.3389/fonc.2023.1047377. PMID: 37265785; PMCID: PMC10229874.

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

- 53. Zhao L, Li Y, Zhang Z, Zou J, Li J, Wei R, Guo Q, Zhu X, Chu C, Fu X, Yue J, Li X. Metaanalysis based gene expression profiling reveals functional genes in ovarian cancer. Biosci Rep. 2020 Nov 27;40(11):BSR20202911. doi: 10.1042/BSR20202911. PMID: 33135729; PMCID: PMC7677829.
- 54. Xi X, Cao T, Qian Y, Wang H, Ju S, Chen Y, Chen T, Yang J, Liang B, Hou S. CDC20 is a novel biomarker for improved clinical predictions in epithelial ovarian cancer. Am J Cancer Res. 2022 Jul 15;12(7):3303-3317. PMID: 35968331; PMCID: PMC9360218.
- 55. Li C, Li W, Zhang Y, Zhang X, Liu T, Zhang Y, Yang Y, Wang L, Pan H, Ji J, Wang C. Increased expression of antisense lncRNA SPINT1-AS1 predicts a poor prognosis in colorectal cancer and is negatively correlated with its sense transcript. Onco Targets Ther. 2018 Jul 10;11:3969-3978. doi: 10.2147/OTT.S163883. PMID: 30022840; PMCID: PMC6044340.
 - 56. Feng H, Gu ZY, Li Q, Liu QH, Yang XY, Zhang JJ. Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis. J Ovarian Res. 2019 Apr 22;12(1):35. doi: 10.1186/s13048-019-0508-2. PMID: 31010415; PMCID: PMC6477749.
- 57. Sehovic E, Hadrovic A, Dogan S. Detection and analysis of stable and flexible genes towards a genome signature framework in cancer. Bioinformation. 2019 Nov 10;15(10):772-779. doi: 10.6026/97320630015772. PMID: 31831960; PMCID: PMC6900328.
- 58. Li N, Li H, Wang Y, Cao L, Zhan X. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. EPMA J. 2020 Oct 10;11(4):661-694. doi: 10.1007/s13167-020-00224-z. PMID: 33240452; PMCID: PMC7680500.
- 59. He WP, Guo YY, Yang GP, Lai HL, Sun TT, Zhang ZW, Ouyang LL, Zheng Y, Tian LM, Li XH, You ZS, Xie D, Yang GF. CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2. Int J Med Sci. 2020 Aug 29;17(15):2387-2395. doi: 10.7150/ijms.48615. PMID: 32922205; PMCID: PMC7484650.
- 656
 60. Soltan MA, Eldeen MA, Eid RA, Alyamani NM, Alqahtani LS, Albogami S, Jafri I, Park MN,
 657
 658
 658
 659
 659
 659
 659
 659
 659
 650
 659
 650
 650
 650
 650
 650
 651
 651
 652
 653
 654
 655
 655
 655
 656
 657
 657
 658
 658
 658
 659
 659
 659
 659
 650
 650
 650
 650
 650
 651
 652
 653
 654
 655
 655
 655
 656
 657
 657
 658
 658
 658
 658
 658
 658
 658
 658
 659
 659
 659
 650
 650
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
- 661 61. He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, Guan XY, Xie D, Yang GF. CHD1L
 662 protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for
 663 patients survival. BMC Cancer. 2012 Sep 29;12:437. doi: 10.1186/1471-2407-12-437. PMID:
 664 23020525; PMCID: PMC3551745.
- 665
 62. Li Y, He LR, Gao Y, Zhou NN, Liu Y, Zhou XK, Liu JF, Guan XY, Ma NF, Xie D. CHD1L
 666
 667
 668
 668
 668
 669
 669
 660
 660
 660
 660
 660
 661
 661
 662
 662
 663
 664
 665
 665
 665
 666
 666
 666
 667
 668
 668
 668
 668
 668
 669
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660
 660<

- 669
 63. Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner RA, Bice J, Kladney RD, Lester J,
 670
 671
 672
 672
 673
 673
 674
 675
 675
 675
 676
 677
 677
 678
 678
 679
 679
 679
 670
 670
 670
 670
 670
 671
 672
 673
 673
 674
 675
 675
 675
 676
 677
 677
 678
 678
 679
 679
 679
 670
 670
 670
 671
 672
 673
 673
 674
 675
 675
 675
 676
 676
 677
 677
 678
 678
 679
 679
 679
 679
 670
 670
 670
 671
 672
 672
 673
 673
 673
 674
 674
 675
 675
 675
 676
 677
 678
 678
 679
 679
 679
 679
 679
 670
 670
 671
 672
 672
 673
 673
 674
 674
 675
 675
 675
 676
 677
 678
 678
 679
 679
 679
 679
 679
 679
 679
 679
 670
 670
 670
 670
 671
 672
 672
 673
 673
 674
 674
 674
 675
 674
 674
 674
 675
 674
 674
 674
 675
 674
 674
 675
 675
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674
 674</
- 674
 64. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH,
 675
 676
 676
 677
 678
 678
 679
 64. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH,
 675
 678
 679
 679
 64. Vizeacoumar FJ, Arnold R, Vizeacoumar FS, Chandrashekhar M, Buzina A, Young JT, Kwan JH,
 675
 678
 679
 679
 670
 670
 671
 672
 673
 673
 674
 674
 675
 675
 675
 675
 676
 677
 678
 678
 679
 679
 679
 670
 670
 670
 671
 672
 673
 674
 674
 675
 675
 675
 675
 676
 677
 678
 678
 679
 679
 679
 670
 670
 670
 671
 672
 673
 674
 674
 675
 675
 675
 674
 675
 675
 675
 675
 676
 677
 77
 78
 79
 79
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70
 70<
 - 65. Zhang C, Xu C, Ma C, Zhang Q, Bu S, Zhang DL, Yu L, Wang H. TRPs in Ovarian Serous Cystadenocarcinoma: The Expression Patterns, Prognostic Roles, and Potential Therapeutic Targets. Front Mol Biosci. 2022 Jun 24;9:915409. doi: 10.3389/fmolb.2022.915409. PMID: 35813831; PMCID: PMC9263218.

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

- 66. Zhang Q, Wang X, Zhang X, Zhan J, Zhang B, Jia J, Chen J. TMEM14A aggravates the progression of human ovarian cancer cells by enhancing the activity of glycolysis. Exp Ther Med. 2022 Aug 5;24(4):614. doi: 10.3892/etm.2022.11551. PMID: 36160886; PMCID: PMC9468797.
 - 67. Tian Y, Zhang J, Chen L, Zhang X. The expression and prognostic role of IMPDH2 in ovarian cancer. Ann Diagn Pathol. 2020 Jun;46:151511. doi: 10.1016/j.anndiagpath.2020.151511. Epub 2020 Mar 23. PMID: 32305001.
- Onallah H, Mannully ST, Davidson B, Reich R. Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D. Int J Mol Sci. 2022 Oct 31;23(21):13286. doi: 10.3390/ijms232113286. PMID: 36362078; PMCID: PMC9658871.
- 69. Li H, Chen L, Tong X, Dai H, Shi T, Cheng X, Sun M, Chen K, Wei Q, Wang M. Functional genetic variants of CTNNBIP1 predict platinum treatment response of Chinese epithelial ovarian cancer patients. J Cancer. 2020 Sep 30;11(23):6850-6860. doi: 10.7150/jca.48218. PMID: 33123276; PMCID: PMC7592014.
 - 70. Caetano MMM, Moreira GA, da Silva MR, Guimarães GR, Santos LO, Pacheco AA, Siqueira RP, Mendes FC, Marques Da Silva EA, Junior AS, Rangel Fietto JL, Saito Â, Boroni M, Bressan GC. Impaired expression of serine/arginine protein kinase 2 (SRPK2) affects melanoma progression. Front Genet. 2022 Sep 23;13:979735. doi: 10.3389/fgene.2022.979735. PMID: 36212152; PMCID: PMC9537589.
 - 71. Jiang C, Yuan B, Hang B, Mao JH, Zou X, Wang P. FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells. Oncol Lett. 2021 Oct;22(4):712. doi: 10.3892/ol.2021.12973. Epub 2021 Aug 5. PMID: 34457067; PMCID: PMC8358613.
 - 72. Li Z, Guo Q, Zhang J, Fu Z, Wang Y, Wang T, Tang J. The RNA-Binding Motif Protein Family in Cancer: Friend or Foe? Front Oncol. 2021 Nov 4;11:757135. doi: 10.3389/fonc.2021.757135. PMID: 34804951; PMCID: PMC8600070.
- 73. Alexandrova E, Pecoraro G, Sellitto A, Melone V, Ferravante C, Rocco T, Guacci A, Giurato G, Nassa G, Rizzo F, Weisz A, Tarallo R. An Overview of Candidate Therapeutic Target Genes in Ovarian Cancer. Cancers (Basel). 2020 Jun 4;12(6):1470. doi: 10.3390/cancers12061470. PMID: 32512900; PMCID: PMC7352306.
- 74. El Khoury W, Nasr Z. Deregulation of ribosomal proteins in human cancers. Biosci Rep. 2021 Dec 22;41(12):BSR20211577. doi: 10.1042/BSR20211577. PMID: 34873618; PMCID: PMC8685657.
- 715 75. Wu F, Liu Y, Hu S, Lu C. Ribosomal protein L31 (RPL31) inhibits the proliferation and migration
 716 of gastric cancer cells. Heliyon. 2023 Jan 20;9(2):e13076. doi: 10.1016/j.heliyon.2023.e13076.
 717 PMID: 36816257; PMCID: PMC9936522.
- 718
 76. Wang L, Sun L, Liu R, Mo H, Niu Y, Chen T, Wang Y, Han S, Tu K, Liu Q. Long non-coding
 719
 718 RNA MAPKAPK5-AS1/PLAGL2/HIF-1α signaling loop promotes hepatocellular carcinoma

720		progression. J Exp Clin Cancer Res. 2021 Feb 17;40(1):72. doi: 10.1186/s13046-021-01868-z.
721		PMID: 33596983; PMCID: PMC7891009.
722	77.	Sha Z, Zhou J, Wu Y, Zhang T, Li C, Meng Q, Musunuru PP, You F, Wu Y, Yu R, Gao S. BYSL
723		Promotes Glioblastoma Cell Migration, Invasion, and Mesenchymal Transition Through the
724		GSK-3β/β-Catenin Signaling Pathway. Front Oncol. 2020 Oct 15;10:565225. doi:
725		10.3389/fonc.2020.565225. PMID: 33178594; PMCID: PMC7593785.
726	78.	Gao S, Sha Z, Zhou J, Wu Y, Song Y, Li C, Liu X, Zhang T, Yu R. BYSL contributes to tumor
727		growth by cooperating with the mTORC2 complex in gliomas. Cancer Biol Med. 2021 Feb
728		15;18(1):88-104. doi: 10.20892/j.issn.2095-3941.2020.0096. PMID: 33628587; PMCID:
729		PMC7877178.
730	79.	Li O. Ren CC, Chen YN, Yang L, Zhang F, Wang BJ, Zhu YH, Li FY, Yang J, Zhang ZA, A Risk
731	,,,,	Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of
732		miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian
733		Cancer Front Cell Dev Biol 2021 Sen 23:0:703060 doi: 10.3380/fcell 2021 703060 PMID:
734		24631700, PMCID: PMC8405156
735	80	Kryazka I. Boncala I. Integrated Bioinformatics Analysis of the Hub Ganas Involved in
735	80.	Irinotocon Basistance in Colorootal Concer Biomodicines 2022 Jul 16:10(7):1720 doi:
730		Innotecan Resistance in Colorectal Cancer. Diomedicines. $2022 \text{ Jul } 10;10(7):1720. \text{ doi:}$
131	01	10.3390/biomedicines100/1/20. PMID: 35885025; PMCID: PMC9512838.
/38	81.	Zhu QY, He ZM, Cao WM, Li B. The role of TSC2 in breast cancer: a literature review. Front
/39		Oncol. 2023 May 12;13:11883/1. doi: 10.3389/fonc.2023.11883/1. PMID: 37251941; PMCID:
740		PMC10213421.
741	82.	Cai J, Sun M, Hu B, Windle B, Ge X, Li G, Sun Y. Sorting Nexin 5 Controls Head and Neck
742		Squamous Cell Carcinoma Progression by Modulating FBW7. J Cancer. 2019 Jun 2;10(13):2942-
743		2952. doi: 10.7150/jca.31055. PMID: 31281471; PMCID: PMC6590026.
744	83.	Lin C, Xin S, Huang X, Zhang F. PTPRA facilitates cancer growth and migration via the TNF-α-
745		mediated PTPRA-NF-kB pathway in MCF-7 breast cancer cells. Oncol Lett. 2020
746		Nov;20(5):131. doi: 10.3892/ol.2020.11992. Epub 2020 Aug 20. PMID: 32934700; PMCID:
747		PMC7471670.
748	84.	Fierheller CT, Alenezi WM, Serruya C, Revil T, Amuzu S, Bedard K, Subramanian DN, Fewings
749		E, Bruce JP, Prokopec S, Bouchard L, Provencher D, Foulkes WD, El Haffaf Z, Mes-Masson
750		AM, Tischkowitz M, Campbell IG, Pugh TJ, Greenwood CMT, Ragoussis J, Tonin PN. Molecular
751		Genetic Characteristics of FANCL a Proposed New Ovarian Cancer Predisposing Gene. Genes
752		(Basel) 2023 Jan 20:14(2):277. doi: 10.3390/genes14020277. PMID: 36833203: PMCID:
753		PMC9956348
754	85	Fierheller CT Guitton-Sert L. Alenezi WM Revil T Oros KK Gao V Bedard K Arcand SI
755	05.	Serriva C Behl S Meunier I Fleury H Fewings F Subramanian DN Nadaf I Bruce IP Bell R
755		Drovensher D. Foulkes WD. El Heffel 7. Mes Messen AM. Meiewelzi I. Dugh TI. Tischkowitz
750		M James DA Comphell IG Greenwood CMT Degoussis I Masson IV Tonin DN A functionally
759		impaired missones variant identified in Energh Canadian families implicates EANCLes a
750		imparted missense variant identified in French Canadian families implicates FANCI as a
139		candidate ovarian cancer-predisposing gene. Genome Med. 2021 Dec 3;13(1):186. doi:
/60	0.6	10.1186/s130/3-021-00998-5. PMID: 34861889; PMCID: PMC86428/7.
/61	86.	Cordas Dos Santos DM, Eilers J, Sosa Vizcaino A, Orlova E, Zimmermann M, Stanulla M,
762		Schrappe M, Börner K, Grimm D, Muckenthaler MU, Kulozik AE, Kunz JB. MAP3K7 is
763		recurrently deleted in pediatric 1-lymphoblastic leukemia and affects cell proliferation
764		independently of NF-κB. BMC Cancer. 2018 Jun 18;18(1):663. doi: 10.1186/s12885-018-4525-0.
765		PMID: 29914415; PMCID: PMC6006985.
766	87.	Sakuma K, Sasaki E, Kimura K, Komori K, Shimizu Y, Yatabe Y, Aoki M. HNRNPLL stabilizes
767		mRNA for DNA replication proteins and promotes cell cycle progression in colorectal cancer
768		cells. Cancer Sci. 2018 Aug;109(8):2458-2468. doi: 10.1111/cas.13660. Epub 2018 Jul 16. PMID:
769		29869816; PMCID: PMC6113449.

770 88. Shi Y, Mo X, Hong S, Li T, Chen B, Chen G. Studying the Role and Molecular Mechanisms of 771 MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma. Biomed Res Int. 2020 Nov 772 5;2020:4965670. doi: 10.1155/2020/4965670. PMID: 33204699; PMCID: PMC7665914. 773 89. Muys BR, Sousa JF, Placa JR, de Araújo LF, Sarshad AA, Anastasakis DG, Wang X, Li XL, de 774 Molfetta GA, Ramão A, Lal A, Vidal DO, Hafner M, Silva WA, miR-450a Acts as a Tumor 775 Suppressor in Ovarian Cancer by Regulating Energy Metabolism. Cancer Res. 2019 Jul 776 1;79(13):3294-3305. doi: 10.1158/0008-5472.CAN-19-0490. Epub 2019 May 17. PMID: 777 31101765; PMCID: PMC6606360. 778 90. Miśkiewicz J, Mielczarek-Palacz A, Gola JM. MicroRNAs as Potential Biomarkers in 779 Gynecological Cancers. Biomedicines. 2023 Jun 13;11(6):1704. doi: 780 10.3390/biomedicines11061704. PMID: 37371799; PMCID: PMC10296063. 781 91. Zhao C, Li Y, Qiu C, Chen J, Wu H, Wang Q, Ma X, Song K, Kong B. Splicing Factor DDX23, 782 Transcriptionally Activated by E2F1, Promotes Ovarian Cancer Progression by Regulating 783 FOXM1. Front Oncol. 2021 Dec 13;11:749144. doi: 10.3389/fonc.2021.749144. PMID: 784 34966670; PMCID: PMC8710544. 785 92. Lisowska KM, Olbryt M, Dudaladava V, Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarząb M, 786 Student S, Rzepecka IK, Jarząb B, Kupryjańczyk J. Gene expression analysis in ovarian cancer -787 faults and hints from DNA microarray study. Front Oncol. 2014 Jan 28:4:6. doi: 788 10.3389/fonc.2014.00006. PMID: 24478986; PMCID: PMC3904181. 789 93. Zhang Z, Zhu Q. WD Repeat and HMG Box DNA Binding Protein 1: An Oncoprotein at the Hub 790 of Tumorigenesis and a Novel Therapeutic Target. Int J Mol Sci. 2023 Aug 6;24(15):12494. doi: 791 10.3390/ijms241512494. PMID: 37569867; PMCID: PMC10420296. 792 94. Xian Q, Zhu D. The Involvement of WDHD1 in the Occurrence of Esophageal Cancer as a 793 Downstream Target of PI3K/AKT Pathway. J Oncol. 2022 Apr 5:2022:5871188. doi: 794 10.1155/2022/5871188. PMID: 35422862; PMCID: PMC9005294. 795 95. Thomas H, Nasim MM, Sarraf CE, Alison MR, Love S, Lambert HE, Price P. Proliferating cell 796 nuclear antigen (PCNA) immunostaining--a prognostic factor in ovarian cancer? Br J Cancer. 797 1995 Feb;71(2):357-62. doi: 10.1038/bjc.1995.72. PMID: 7841053; PMCID: PMC2033602. 798 96. Zhu X, You S, Du X, Song K, Lv T, Zhao H, Yao Q. LRRC superfamily expression in stromal 799 cells predicts the clinical prognosis and platinum resistance of ovarian cancer. BMC Med 800 Genomics. 2023 Jan 18;16(1):10. doi: 10.1186/s12920-023-01435-9. PMID: 36653841; PMCID: 801 PMC9850808. 802 97. Wu J, Lu F, Yu B, Wang W, Ye X. The oncogenic role of SNRPB in human tumors: A pan-cancer 803 analysis. Front Mol Biosci. 2022 Oct 6;9:994440. doi: 10.3389/fmolb.2022.994440. PMID: 804 36275630; PMCID: PMC9582665. 805 98. Dogan B, Gumusoglu E, Ulgen E, Sezerman OU, Gunel T. Integrated bioinformatics analysis of 806 validated and circulating miRNAs in ovarian cancer. Genomics Inform. 2022 Jun;20(2):e20. doi: 807 10.5808/gi.21067. Epub 2022 Jun 30. PMID: 35794700; PMCID: PMC9299562. 808 99. Wagenbach M, Vicente JJ, Ovechkina Y, Domnitz S, Wordeman L. Functional characterization of 809 MCAK/Kif2C cancer mutations using high-throughput microscopic analysis. Mol Biol Cell. 2020 810 Mar 19;31(7):580-588. doi: 10.1091/mbc.E19-09-0503. Epub 2019 Nov 20. PMID: 31746663; 811 PMCID: PMC7202071. 812 100. Tong D, Volm T, Eberhardt E, Krainer M, Leodolter S, Kreienberg R, Zeillinger R. Rad52 813 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. Oncol 814 Rep. 2003 Sep-Oct;10(5):1551-3. PMID: 12883740. 815 Diao Y, Li Y, Wang Z, Wang S, Li P, Kong B. SF3B4 promotes ovarian cancer 101. 816 progression by regulating alternative splicing of RAD52. Cell Death Dis. 2022 Feb 24;13(2):179. 817 doi: 10.1038/s41419-022-04630-1. PMID: 35210412; PMCID: PMC8873359. 818 102. Challa S, Khulpateea BR, Nandu T, Camacho CV, Ryu KW, Chen H, Peng Y, Lea JS, 819 Kraus WL. Ribosome ADP-ribosylation inhibits translation and maintains proteostasis in cancers.

- 820 Cell. 2021 Aug 19;184(17):4531-4546.e26. doi: 10.1016/j.cell.2021.07.005. Epub 2021 Jul 26.
 821 PMID: 34314702; PMCID: PMC8380725.
- 103. Cao M, Deng Y, Deng Y, Wu J, Yang C, Wang Z, Hou Q, Fu H, Ren Z, Xia X, Li Y, Wang
 W, Xu H, Liao X, Shu Y. Characterization of immature ovarian teratomas through single-cell
 transcriptome. Front Immunol. 2023 Mar 3;14:1131814. doi: 10.3389/fimmu.2023.1131814.
 PMID: 36936909; PMCID: PMC10020330.
- 826